Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 9/20 | 0.56 |
| ▸ | NPY1R | P25929 | 1/20 | 0.52 |
| ▸ | TPSAB1 | Q15661 | 5/20 | 0.43 |
| ▸ | TPSD1 | Q9BZJ3 | 5/20 | 0.43 |
| ▸ | TPSG1 | Q9NRR2 | 5/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 3/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4177837 | 1.00 | APP (0.56) | APPNPY1RTPSAB1TPSD1TPSG1 | |
| SCHEMBL4467224 | 0.84 | APP (0.53) | APPNPY1RTPSAB1TPSD1TPSG1 | |
| SCHEMBL4177839 | 0.84 | APP (0.53) | APPNPY1RTPSAB1TPSD1TPSG1 | |
| SCHEMBL4349231 | 0.83 | KMT2A (0.53) | APPF10 | |
| SCHEMBL6198420 | 0.82 | L3MBTL1 (0.47) | ACESIRT1 | |
| SCHEMBL7419635 | 0.79 | SIRT2 (0.53) | NPY1RSIRT1 | |
| SCHEMBL7829097 | 0.77 | HDAC1 (0.49) | SIRT1 | |
| SCHEMBL4703615 | 0.77 | ACE (0.47) | ACE | |
| Trifluoroacetic Acid SCHEMBL7421812 | 0.76 | F10 (0.51) | F10 | |
| SCHEMBL4193840 | 0.76 | NPY1R (0.60) | APPNPY1RTPSAB1TPSD1TPSG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070027132-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of Alphabeta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-02-01 | — | — | US | claimed |
| US-6960576-B2 | Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-01 | — | — | US | claimed |
| US-20050113363-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of A beta protein production | OLSON RICHARD E (US) | 2005-05-26 | — | — | US | claimed |
| US-20030166636-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of A-beta protein production | OLSON RICHARD E (US) | 2003-09-04 | — | — | US | claimed |
| EP-1212306-A2 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-06-12 | — | — | EP | claimed |
| US-20020052360-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-02 | — | — | US | claimed |
| WO-2001019797-A2 | HYDROXYALKANOYL AMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-03-22 | — | — | WO | claimed |
| US-20090111793-A1 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-04-30 | — | — | US | disclosed |
| US-7423033-B2 | Hydroxyalkanoylaminolactams and related structures as inhibitors of aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-09-09 | — | — | US | disclosed |
| US-20080132482-A1 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-06-05 | — | — | US | disclosed |
| US-7342008-B2 | Containing a benzodiazepine ring; 2-Cyclopentylmethyl-3(S)-hydroxyl-1-oxo-5-phenylpentyl)amino-1-methyl-5-(4-fluoro-phenyl)-2,3-dihydro-1H-1,5-benzodiazepin-2-one; Alzheimer's disease and Down's Syndrome; prevent the formation of neurological deposits of amyloid protein | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-03-11 | — | — | US | disclosed |
| US-20070027132-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of Alphabeta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-02-01 | — | — | US | disclosed |
| US-7112583-B2 | Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-09-26 | — | — | US | disclosed |
| US-6960576-B2 | Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050113363-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of A beta protein production | OLSON RICHARD E (US) | 2005-05-26 | — | — | US | disclosed |
| US-20030166636-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of A-beta protein production | OLSON RICHARD E (US) | 2003-09-04 | — | — | US | disclosed |
| US-6503902-B2 | Treatment of neurological disorders related to beta -amyloid production such as Alzheimer's disease and Down's Syndrome. | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-07 | — | — | US | disclosed |
| EP-1212306-A2 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-06-12 | — | — | EP | disclosed |
| US-20020052360-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-02 | — | — | US | disclosed |
| WO-2001019797-A2 | HYDROXYALKANOYL AMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027132-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of Alphabeta protein production | APP, BACE1, APH1A | APP 1/4885NPY1R 2702/4885TPSAB1 75/4885 |
| US-20080132482-A1 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | APP, BACE1, APH1A | APP 1/4885NPY1R 2872/4885TPSAB1 142/4885 |
| US-20030166636-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of A-beta protein production | APP, APH1A, APH1B | APP 1/4885NPY1R 2295/4885TPSAB1 139/4885 |
| US-20020052360-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of a beta protein production | APP, APH1A, BACE1 | APP 1/4885NPY1R 2635/4885TPSAB1 137/4885 |
| US-20050113363-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of A beta protein production | APP, BACE1, APH1A | APP 1/4885NPY1R 2872/4885TPSAB1 142/4885 |
| US-20090111793-A1 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | APP, BACE1, APH1A | APP 1/4885NPY1R 2872/4885TPSAB1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.